This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Allan L. Lorincz, MD

Arch Dermatol. 1994;130(6):781-782.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INFLAMMATORY CELL-MEDIATED tissue injury is a final common pathway in the pathogenetic mechanisms of many skin diseases. Dermatologic observations and investigative studies on a wide variety of therapeutic agents and modalities, which have anti-inflammatory efficacy, have often pioneered in discovering new directions and understanding about the control of such inflammatory tissue injury. In addition to their practical usefulness in the treatment of skin diseases, these dermatologic contributions have had applications in the treatment of a variety of other medical disorders, especially those in which complement activation via either the classic or alternative pathway activates neutrophilic tissue injury as occurs, for example, in a number of vasculitides and rheumatoid arthritis. It is likely that many further opportunities for their beneficial exploitation await wider medical exploration.

Dermatologists were the first to recognize that certain antimicrobial agents had anti-inflammatory pharmacologic activity unrelated to their antibacterial activity. Sulzberger¹ in 1939 reported the successful . . . [Full Text PDF of this Article]

Author Affiliations
Section of Dermatology Department of Medicine University of Chicago 5841 S Maryland MC 5067 Chicago, IL 60637

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?